HYPEREOSINOPHILIC SYNDROME
Clinical trials for HYPEREOSINOPHILIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HYPEREOSINOPHILIC SYNDROME trials appear
Sign up with your email to follow new studies for HYPEREOSINOPHILIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer drug shows promise for rare blood disorder
Disease control OngoingThis study tests whether imatinib (Gleevec) can safely reduce high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES). About 70 participants with the myeloid form of HES or those who did not respond to steroids will take imatinib da…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New shot may tame rare blood disease flares
Disease control OngoingThis study tests an injected drug called benralizumab in people with hypereosinophilic syndrome (HES), a rare condition where too many white blood cells cause organ damage. About 134 participants aged 12 and older will receive either benralizumab or a placebo every 4 weeks for 24…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 22, 2026 13:52 UTC